Clinicopathological characteristics, genetics and prognosis of patients with myeloid sarcoma: a single-center study

Basit Öğe Kaydı
dc.authoridULUSOY, Yusuf/0000-0002-4408-3544
dc.authoridDEMIR, DERYA/0000-0002-6333-8856
dc.authorscopusid34768054600
dc.authorscopusid6701598632
dc.authorscopusid6602888517
dc.authorscopusid57440306700
dc.authorscopusid57203864701
dc.authorscopusid6701575271
dc.authorscopusid23472577300
dc.contributor.authorDemir, Derya
dc.contributor.authorHekimgi, Mine
dc.contributor.authorKaraca, Emin
dc.contributor.authorUlusoy, Yusuf
dc.contributor.authorOzdemir, Hamiyet Hekimci
dc.contributor.authorSaydam, Guray
dc.contributor.authorDurmaz, Burak
dc.date.accessioned2023-01-12T20:03:01Z
dc.date.available2023-01-12T20:03:01Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractAim Myeloid sarcoma (MS) is a rare tumour comprising myeloid blasts occurring at an anatomical site other than the bone marrow. We sought to investigate both paediatric and adult patients with MS diagnosed at our institution and determine possible correlations among their clinicopathological, phenotypic, molecular and prognostic features. Methods This study retrospectively evaluated the data of 45 patients diagnosed with MS at Ege University Faculty of Medicine Hospital, Turkey, over a 17-year period. Results The male-to-female ratio was 1.5:1, and the median age was 39.12 years. The most commonly involved sites were the skin, lymph nodes, soft tissues and bone. Immunohistochemically, CD68-KP1 was the most commonly expressed marker, followed by CD33, myeloperoxidase, CD117, lysozyme, CD68-PGM1 and CD34. Of the patients, 26 (57.7%) presented with de novo MS, 7 (15.5%) had simultaneous acute myeloid leukaemia and 12 (26.8%) had a previous history of haematological disorders. Kaplan-Meier survival analysis revealed that the 2-year and 5-year overall survival (OS) rates were 46.4% and 39.8%, respectively; the median OS duration was 11 months. Increasing age had a negative prognostic relationship with survival (p = 0.04). Chromosomal abnormalities were detected in approximately 6/10 (60%) of paediatric patients and 6/9 (66.7%) of adult patients. t(8;21)(q22;q22) translocation was identified in 20% of paediatric patients. Conclusions MS diagnosis is usually challenging; an expanded immunohistochemical panel should be used for an accurate diagnosis. Although MS generally has a poor prognosis, increasing age appears to be associated with a worse outcome.en_US
dc.identifier.doi10.1136/jcp-2021-208000
dc.identifier.issn0021-9746
dc.identifier.issn1472-4146
dc.identifier.pmid35927017en_US
dc.identifier.scopus2-s2.0-85135885206en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1136/jcp-2021-208000
dc.identifier.urihttps://hdl.handle.net/11454/77649
dc.identifier.wosWOS:000837261000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmj Publishing Groupen_US
dc.relation.ispartofJournal of Clinical Pathologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectmyeloid sarcomaen_US
dc.subjectchloromaen_US
dc.subjectgranulocytic sarcomaen_US
dc.subjectgeneticen_US
dc.subjectprognosisen_US
dc.subjectHealth-Organization Classificationen_US
dc.subjectAcute Lymphoblastic-Leukemiaen_US
dc.subjectGranulocytic Sarcomaen_US
dc.subjectGemtuzumab Ozogamicinen_US
dc.subject2016 Revisionen_US
dc.subjectBone-Marrowen_US
dc.subjectCell Tumorsen_US
dc.subjectCd33en_US
dc.subjectChemotherapyen_US
dc.subjectDiagnosisen_US
dc.titleClinicopathological characteristics, genetics and prognosis of patients with myeloid sarcoma: a single-center studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu